Skip to main content

KILL Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials

 

Aditxt, Inc. requests that their press release NewsItemId: 20250414955183 issued April 14, 2025 “Aditxt Subsidiary Adimune Announces Positive Results from Mayo Clinic Pre-Clinical Studies to Support FDA and European Regulatory Submissions for Type 1 Diabetes, Psoriasis, and Stiff Person Syndrome Human Trials” be killed.

The release was issued in error by Aditxt, Inc.

A replacement release will not be issued at this time.

Contacts

Aditxt, Inc. 

Corporate Communications 

Jeff Ramson, PCG Advisory, Inc. 

T: 646-863-6893 

contactus@aditxt.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  206.03
+1.17 (0.57%)
AAPL  258.81
-1.77 (-0.68%)
AMD  200.21
-3.16 (-1.55%)
BAC  52.14
-0.63 (-1.19%)
GOOG  309.09
+5.53 (1.82%)
META  649.24
+4.46 (0.69%)
MSFT  397.34
-1.12 (-0.28%)
NVDA  187.67
-0.23 (-0.12%)
ORCL  152.12
-4.42 (-2.82%)
TSLA  408.23
-3.48 (-0.85%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.